Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: A comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 151-155

  Dancer, Jane ^a   Takei, Hidehiro ^a   Ro, Jae Y ^a   Lowery Nordberg, Mary ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Epidermal growth factor receptor; HER 2; Pancreatic ductal adenocarcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 34548039272     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.151     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer Statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
2. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J and Kloppel R: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 54: 385-387, 2005. (Pubitemid 40299095)
3. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA and Gullick WJ: The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166: 7-12, 1992.
4. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanka M, Inokuchi S and Makuuchi H: Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 11: 305-309, 2003.
5. Hirsch FR, Varella-Garcia M, MaCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J and Gandara DR: Increased epidermal growth factor receptor gene copy detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchiolar alveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23: 6838-6845, 2005.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 12: 1490-1500, 2004.
7. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN and Harber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
8. Engelman JA and Cantley LC: The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12: S4372-S4376, 2006.
9. Day JD, Digiuseppe JA, Yeo C, Lai-Goldman M, Anderson SM, Goodman SN, Kern SE and Hruban RH: Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27: 119-124, 1996. (Pubitemid 26049464)
10. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL and Hirsh FR: Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor positive non-small cell lung cancer patients. J Clin Oncol 23: 5007-5018, 2005. (Pubitemid 46224007)
11. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ and Lemmon MA: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517, 2003. (Pubitemid 36297057)
12. Salomon DS, Brandt R, Ciardiello F and Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
13. Normanno N, Bianco C, De Luca A and Salomon DS: The role of EGF-related peptides in tumor growth. Front Biosci 6: 685-707, 2001.
14. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW and Yokoyama S: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-542, 2003.
15. Karunagaran D, Tzahar E, Beerli RR, Chen X, Hynes NE, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE and Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254-264, 1996. (Pubitemid 26029205)
16. Ross JS and Fletcher JA: The HER-2/neu Oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3: 237-252, 1998.
17. Di Giovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D and Thor AD: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 23: 1152-1160, 2005. (Pubitemid 46202271)
18. Normanno N, De Luca A, Bianco C, Strizzi C, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salmon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16, 2006. (Pubitemid 43199589)
19. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and Her2 status and absence of EGFR-activating mutations. Mod Pathol 18: 1027-1033, 2005. (Pubitemid 41224492)
20. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R and Buttitta F: EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857-865, 2005. (Pubitemid 46224186)
21. Willmore-Payne C, Holden JA and Layfield LJ: Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol 37: 755-763, 2006. (Pubitemid 43956548)
22. Johnson BE and Janne PA: Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a table of mutations. J Clin Oncol 23: 6813-6816, 2005.
23. Al-Kuraya K, Sirj AK, Bavi P, Al-Jommah N, Ezzat A, Sheikh S, Amr S, Al-Dayel F, Simon R and Guido S: High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol 37: 453-457, 2006.
24. Immervoll H, Hoem D, Kugarajh K, Steine SJ and Molven A: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 448: 788-796, 2006. (Pubitemid 43824436)
25. Blaszkowsky LS, Kulke KH and Ryan DP: A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 23 (Suppl 16): 4099a, 2005.
26. Moore MJ, Goldstein D and Hamm J: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol 239 (Suppl 16): 1a, 2005.
27. Akiyama T, Sudo C, Ogawara H, Toyoshima H and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosin kinase activity. Science 232: 1644-1646, 1986. (Pubitemid 16095607)
28. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986. (Pubitemid 16128785)
29. Safran H, Stainhoff H, Mangray S, Rathore R, King TC, Chai L, Berzein K, Moore T, Iannitti D, Reiss P, Pasquariello T, Akerman P, Quirk D, Mass R, Goldstein L and Tantravahi U: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24: 496-499, 2001. (Pubitemid 32959109)
30. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A and Smoth RC: Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29: 1125-1134, 2005. (Pubitemid 41232983)
31. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD and Gazdar AF: Somatic mutations of the HER2 kinase domain in lung adenocarcinoma. Cancer Res 65: 1642-1646, 2005. (Pubitemid 40478587)
32. Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC and Yarden Y: ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 18: 6090-6101, 1998. (Pubitemid 28450560)
33. Mosesson Y and Yarden Y: Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 14: 262-270, 2004. (Pubitemid 38824587)